New Guidelines for Lung Cancer Improve Eligibility Among Minorities, But Don’t Close Racial Gap
An analysis of the latest US Preventive Services Task Force (USPSTF) lung cancer screening guideline for screening eligibility found that while improvements were made...
Dr. Camidge Discusses Launch of Phase 2 Trial Evaluating RAF/MEK Inhibitor in NSCLC
Verastem Oncology recently announced the initiation of the second phase 2 registration-directed clinical trial from its RAMP (Raf And Mek Program). The study, RAMP...
Tagrisso Approved as Adjuvant Therapy for NSCLC With EGFR Mutations
TUESDAY, Dec. 22, 2020 (HealthDay News) -- Tagrisso (osimertinib) received approval as an adjuvant treatment for patients with non-small cell lung cancer with epidermal...
Hem/Onc Roundup: Lung Cancer Screenings Decline, Insurance Status Linked to Myeloma Survival, and More
Study: Lung Cancer Screening Amid the COVID-19 Pandemic
A review found a decline in lung cancer screening, but an overall rise in malignancies since the COVID-19...
Are Lung Cancer Treatment and Survival Different for Patients with Autoimmune Diseases?
Patients with autoimmune diseases—including rheumatoid arthritis (RA)—do not have poorer lung cancer survival compared to patients without autoimmune disease, but they are less likely...
Amivantamab Seeks FDA Nod for Non-Small Cell Lung Cancer
Janssen Pharmaceuticals has submitted a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for approval of amivantamab for the treatment...
State of Lung Cancer Report Highlights Racial Disparities
This year, the American Lung Association’s State of Lung Cancer report examined, for the first time, racial and ethnic disparities in lung cancer diagnoses...
